File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Rotavirus vaccine RIX4414 efficacy sustained during the third year of life: A randomized clinical trial in an Asian population

TitleRotavirus vaccine RIX4414 efficacy sustained during the third year of life: A randomized clinical trial in an Asian population
Authors
Phua, KBLim, FSLau, YLNelson, EASHuang, LMQuak, SHLee, BWDoorn, LJVTeoh, YLTang, HSuryakiran, PVSmolenov, IVBock, HLHan, HH
Keywords3Years
Efficacy
Gastroenteritis
Rix4414
Rotavirus
Issue Date2012
PublisherElsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/vaccine
Citation
Vaccine, 2012, v. 30 n. 30, p. 4552-4557 How to Cite?
DOI: http://dx.doi.org/10.1016/j.vaccine.2012.03.030
AbstractRIX4414 (Rotarix™), has shown high efficacy during the first 2-years of life. A 2-year randomized, double-blind, placebo-controlled trial in Singapore, Hong Kong, and Taiwan was extended for another year. Infants (6-17. weeks) received 2-doses (1-2. months apart) of RIX4414 (n= 5359) or placebo (n= 5349). During the third-year follow-up, 4359 (RIX4414) and 4328 (placebo) infants were monitored. 64 (1.2%) and 2 (0.04%) infants in the placebo and RIX4414 groups, respectively, reported severe rotavirus-gastroenteritis (RVGE), resulting in a vaccine efficacy of 96.9% (95% CI [88.3-99.6]). Efficacy was 100% (67.5-100) in the third-year. RIX4414 was efficacious against G1 (100.0% [84.8-100]) and pooled non-G1 RV types (94.9% [80.2-99.4]). This study shows that the vaccine is highly efficacious, regardless of circulating RV-types, up to the first 3. years of life in affluent Asian urban populations. © 2012 Elsevier Ltd.
Persistent Identifierhttp://hdl.handle.net/10722/170465
ISSN
0264-410X
2023 Impact Factor: 4.5
2023 SCImago Journal Rankings: 1.342
ISI Accession Number ID
WOS:000310117100020
References
References in Scopus

 

DC FieldValueLanguage
dc.contributor.authorPhua, KBen_US
dc.contributor.authorLim, FSen_US
dc.contributor.authorLau, YLen_US
dc.contributor.authorNelson, EASen_US
dc.contributor.authorHuang, LMen_US
dc.contributor.authorQuak, SHen_US
dc.contributor.authorLee, BWen_US
dc.contributor.authorDoorn, LJVen_US
dc.contributor.authorTeoh, YLen_US
dc.contributor.authorTang, Hen_US
dc.contributor.authorSuryakiran, PVen_US
dc.contributor.authorSmolenov, IVen_US
dc.contributor.authorBock, HLen_US
dc.contributor.authorHan, HHen_US
dc.date.accessioned2012-10-30T06:09:11Z-
dc.date.available2012-10-30T06:09:11Z-
dc.date.issued2012en_US
dc.identifier.citationVaccine, 2012, v. 30 n. 30, p. 4552-4557en_US
dc.identifier.issn0264-410Xen_US
dc.identifier.urihttp://hdl.handle.net/10722/170465-
dc.description.abstractRIX4414 (Rotarix™), has shown high efficacy during the first 2-years of life. A 2-year randomized, double-blind, placebo-controlled trial in Singapore, Hong Kong, and Taiwan was extended for another year. Infants (6-17. weeks) received 2-doses (1-2. months apart) of RIX4414 (n= 5359) or placebo (n= 5349). During the third-year follow-up, 4359 (RIX4414) and 4328 (placebo) infants were monitored. 64 (1.2%) and 2 (0.04%) infants in the placebo and RIX4414 groups, respectively, reported severe rotavirus-gastroenteritis (RVGE), resulting in a vaccine efficacy of 96.9% (95% CI [88.3-99.6]). Efficacy was 100% (67.5-100) in the third-year. RIX4414 was efficacious against G1 (100.0% [84.8-100]) and pooled non-G1 RV types (94.9% [80.2-99.4]). This study shows that the vaccine is highly efficacious, regardless of circulating RV-types, up to the first 3. years of life in affluent Asian urban populations. © 2012 Elsevier Ltd.en_US
dc.languageengen_US
dc.publisherElsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/vaccineen_US
dc.relation.ispartofVaccineen_US
dc.subject3Yearsen_US
dc.subjectEfficacyen_US
dc.subjectGastroenteritisen_US
dc.subjectRix4414en_US
dc.subjectRotavirusen_US
dc.titleRotavirus vaccine RIX4414 efficacy sustained during the third year of life: A randomized clinical trial in an Asian populationen_US
dc.typeArticleen_US
dc.identifier.emailLau, YL:lauylung@hkucc.hku.hken_US
dc.identifier.authorityLau, YL=rp00361en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1016/j.vaccine.2012.03.030en_US
dc.identifier.pmid22497874-
dc.identifier.scopuseid_2-s2.0-84862020627en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-84862020627&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume30en_US
dc.identifier.issue30en_US
dc.identifier.spage4552en_US
dc.identifier.epage4557en_US
dc.identifier.isiWOS:000310117100020-
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridPhua, KB=7003538202en_US
dc.identifier.scopusauthoridLim, FS=7006112665en_US
dc.identifier.scopusauthoridLau, YL=7201403380en_US
dc.identifier.scopusauthoridNelson, EAS=7402264387en_US
dc.identifier.scopusauthoridHuang, LM=24281436100en_US
dc.identifier.scopusauthoridQuak, SH=35512093800en_US
dc.identifier.scopusauthoridLee, BW=7405437980en_US
dc.identifier.scopusauthoridDoorn, LJV=16244783500en_US
dc.identifier.scopusauthoridTeoh, YL=6603277028en_US
dc.identifier.scopusauthoridTang, H=15828580700en_US
dc.identifier.scopusauthoridSuryakiran, PV=26022588400en_US
dc.identifier.scopusauthoridSmolenov, IV=23499725700en_US
dc.identifier.scopusauthoridBock, HL=7201825902en_US
dc.identifier.scopusauthoridHan, HH=8545352800en_US
dc.identifier.citeulike10784864-
dc.identifier.issnl0264-410X-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats